In contrast, the reliability of FGFR2–4 amplification (which is rare in Sq-NSCLC [0–4.7%], Table 1) (11, 20, 22, 36, 53) as a predictive biomarker for Sq-NSCLC has not been investigated. Here, FGFR2 is linked to non-small cell lung carcinoma.